Thursday, May 4, 2023
CONTINENTAL BREAKFAST
8:00 - 9:00
Introduction to the Programme
Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada
William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics,
McGill University, Montréal, QC, Canada
Remembering David Livingston, MD (1941-2021)
Introduction:
William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics,
McGill University, Montréal, QC, Canada
Speaker:
Judy Garber, MD, MPH, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
New developments in HBOC management
CHAIR: Tuya Pal, MD, Vanderbilt – Ingram Cancer Center, Nashville, TN, USA
9:30 - 9:50
LECTURE
Treatment (and prevention) of BRCA1/2-related breast cancer – Platinums, PARPs and beyond
Judy Garber, MD, MPH, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
9:50 - 10:10
LECTURE
Is cure of hereditary ovarian cancer an achievable goal?
Jonathan Ledermann, MD, University College London, London, UK
10:10 - 10:20
PROFFERED PAPER 1 (S7-PP1)
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis
Kelly Metcalfe, RN, PhD, Kelly Metcalfe, RN, PhD, Women's College Research Institute, Toronto, ON, Canada
10:24 - 10:27
RAPID FIRE POSTER PRESENTATIONS (S7-RF1)
Early salpingectomy with delayed oophorectomy as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 pathogenic variant carriers - Update of the TUBA-WISP II study
Majke van Bommel, PhD candidate, Radboud University Medical Center, Nijmegen, The Netherlands
10:27 - 10:30
RAPID FIRE POSTER PRESENTATIONS (S7-RF2)
Bilateral oophorectomy and all-cause mortality in women with BRCA1 pathogenic variants
Joanne Kotsopoulos, PhD, Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
10:30 - 10:33
RAPID FIRE POSTER PRESENTATIONS (S7-RF3)
Describing the real world experience of implementing a pre-test genetic counselling portal within a provincial hereditary cancer program
Jennifer Nuk, MSc, BC Cancer Hereditary Cancer Program, Vancouver, BC, Canada
10:33 - 10:36
RAPID FIRE POSTER PRESENTATIONS (S7-RF4)
Novel blood-based biomarker to monitor neoadjuvant therapy outcome In triple-negative breast cancer patients
Srinidi Mohan, PhD, University of New England, Portland, ME, United States
10:40 - 11:00
Question and discussion period (all speakers)
Special Interest Groups (SIGs)
Moderated 90-minute interactive discussions with the aim of fostering bilateral knowledge transfer. Choice of one of the following 3 SIGs.
SIG 4:
The Emotional Pedigree: addressing the heart of complex psychosocial issues in genetic counseling sessions with HBOC patients
Using an all-new series of cases, we will contrast the abstract symbols of the pedigree with the emotionally fraught situations they represent, in order to identify psychosocial challenges that affect patient decision-making and ability to absorb risk information. We will practice applying psychosocial techniques that can be incorporated into genetic counseling sessions.
Karen Hurley, PhD, Cleveland Clinic, Cleveland, OH, USA
SIG 5:
Exploring cut-offs: When is the risk high enough to consider salpingo-oophorectomy?
In this session, the three presenters will discuss genetic predisposition to ovarian cancer and associated risks, prediction of personalised ovarian cancer risk, the health economics supporting different thresholds for salpingo-oophorectomy and the balance of risk versus side effects of an early menopause. Attendees will participate in the discussion via interactive polls and will be encouraged to send in questions relating to these topics in advance for discussion at the SIG.
Helen Hanson, MBBS, MD(Res),
St George's Hospital, London, UK (session lead)
Lesa Dawson, MD, FRCSC, University of British Columbia, Vancouver, BC, Canada
-
Ranjit Manchanda, MD, MRCOG, PhD, Wolfson Institute of Population Health, Queen Mary University of London, London, UK
SIG 6:
CanRisk Workshop – Multifactorial breast and ovarian cancer risk prediction
This will be an interactive session for health professionals who are not familiar with the Canrisk tool (www.canrisk.org) for predicting multifactorial breast and ovarian cancer risks. There will be a live demonstration of the tool and a discussion of the most frequently asked questions by users. Attendees are encouraged to register as CanRisk users in advance of the SIG and will carry out risk predictions (participants will need to bring a laptop).
Antonis Antoniou, PhD, University of Cambridge, Cambridge, UK (session lead)
Marc Tischkowitz, MD, PhD, University of Cambridge, Cambridge, UK
LUNCH BREAK
13:00 - 14:30
Polygenic risk scores in practice
CHAIR: Jacques Simard, PhD, FRSC, FCAHS, Centre de recherche du CHU de Québec - Université Laval, Québec, QC, Canada
14:30 - 14:50
LECTURE
Polygenic risk scores and moderate risk genes
Paul James, MD, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
14:50 - 15:10
LECTURE
Will polygenic risk scores for cancer ever be clinically useful?
Clare Turnbull, MD, PhD, MFPH, Institute of Cancer Research, London, UK
15:10 - 15:20
PROFFERED PAPER 1 (S8-PP1)
Implementation of risk stratified breast cancer screening: clinical use of multifactorial risk assessment including polygenic risk scores to guide recommendations
Anna M. Chiarelli, PhD, MHSc, Ontario Health, Toronto, ON, Canada
15:20 - 15:30
PROFFERED PAPER 2 (S8-PP2)
Addition of breast density (BD) and polygenic risk score (PRS) In breast cancer (BC) risk estimation among women with family history (PRiSma Study)
Judith Balmaña, MD, PhD, Judith Balmaña, MD, PhD, University Hospital Vall d'Hebron, Barcelona, Spain
15:30 - 15:40
PROFFERED PAPER 3 (S8-PP3)
Comparison of the impact of integrating BRCA1 and BRCA2 pathogenic variants and polygenic risk score for individual genetic risk estimation in three cancer types
Ryoko Yamada, PhD, RIKEN, Yokohama, Kanagawa, Japan
15:40 - 16:00
Question and discussion period (all speakers)
POSTER SESSION 2 (with break)
16:00 - 17:30